摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxyphenyl]-N-(1-ethylpyrazol-4-yl)acetamide | 1374784-87-8

中文名称
——
中文别名
——
英文名称
2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxyphenyl]-N-(1-ethylpyrazol-4-yl)acetamide
英文别名
——
2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxyphenyl]-N-(1-ethylpyrazol-4-yl)acetamide化学式
CAS
1374784-87-8
化学式
C24H25N5O5
mdl
——
分子量
463.493
InChiKey
CZSOWVHBIBQBJU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    34
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    110
  • 氢给体数:
    1
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    2-[4-(6,7-dimethoxyquinazolin-4-yloxy)-2-methoxyphenyl]acetic acid 、 4-氨基-1-乙基吡唑2-羟基吡啶-N-氧化物盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 14.0h, 以38%的产率得到2-[4-(6,7-dimethoxyquinazolin-4-yl)oxy-2-methoxyphenyl]-N-(1-ethylpyrazol-4-yl)acetamide
    参考文献:
    名称:
    Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases
    摘要:
    A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.03.074
点击查看最新优质反应信息

文献信息

  • Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases
    作者:Patrick A. Plé、Frédéric Jung、Sue Ashton、Laurent Hennequin、Romuald Laine、Christine Lambert-van der Brempt、Rémy Morgentin、Georges Pasquet、Sian Taylor
    DOI:10.1016/j.bmcl.2012.03.074
    日期:2012.5
    A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFR alpha and beta, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多